Gan & Lee und die Menarini Group schließen Partnerschaft zur Weiterentwicklung von Bofanglutide in Europa

Gan & Lee hat eine exklusive Lizenzpartnerschaft mit der Menarini Group für den GLP-1-RA Bofanglutide (GZR18) in Europa (39 Länder) abgeschlossen. Gan & Lee erhält 62 Mio. EUR Vorauszahlung, bis zu 664 Mio. EUR Meilensteine sowie zweistellige Lizenzgebühren auf den Nettoumsatz; der Gesamttransaktionswert liegt bei bis zu 726 Mio. EUR (ohne Lizenzgebühren). Die Partnerschaft zielt darauf, die Zulassungs- und Vermarktungsaktivitäten für das 2-wöchentlich dosierte Produkt (q2w) zu beschleunigen; Phase-3 (China) und Phase-2 (USA) erreichten die primären Endpunkte zur Gewichtsreduktion.

Analysis

This is more of a credibility event than an earnings event. For Gan & Lee, the real value is not the upfront cash; it is the external validation that can compress the discount applied to Chinese originator biotech, especially when the asset is being handed to a European commercial partner rather than priced as a purely domestic story. The longer-term winner could be Menarini if it can use a differentiated dosing schedule to win payer/access conversations in Europe, but that only matters if phase-3 data show parity or better durability versus established GLP-1s.

The competitive threat to NVO/LLY looks limited near term. A q2w regimen is a plausible adherence advantage, but obesity adoption is still dominated by efficacy, tolerability, supply reliability, and reimbursement. Unless Bofanglutide shows meaningfully lower discontinuation or superior convenience at comparable weight loss, incumbents should absorb it as a niche rather than a market-share event. The more interesting second-order effect is on Chinese biotech financing: successful out-licensing into regulated markets can re-rate other China innovators that have been viewed as “domestic-only” assets.

Catalyst path is long. Near term, the stock reaction may overshoot on the deal headline, but the next hard inflection is global phase-3 initiation and, later, whether the regimen can show commercial differentiation beyond standard GLP-1 class effects. The key falsifier is delay or dependence on large new capital raises before that program starts. Consensus may be overstating near-term revenue and understating execution risk; this is an option on future regulatory success, not a de-risked franchise shift yet.

Key Decisions for Investors

• Long 603087.SH on pullbacks over the next 1-2 weeks if the market treats this as a durable re-rating catalyst; target is a 10-20% move on pipeline optionality, with a hard stop if global phase-3 timelines slip beyond 2 quarters.
• Avoid shorting NVO or LLY on this news alone; the competitive read-through is too early and the asset still needs large-scale confirmation in Europe before it can pressure incumbent growth.
• Watch for confirmation of global phase-3 start within 3-6 months; if management funds it without heavy dilution, add to the long thesis, but if financing appears first, treat the move as exhausted.
• For risk-managed exposure, consider a call-spread style expression on 603087.SH rather than outright leverage; the upside is event-driven, but the downside is execution and regulatory slippage over 6-18 months.
• Set an alert on any change in Menarini’s commercial language or EU trial registry activity; that is the earliest verifiable signal that this becomes a real obesity-market challenger rather than a PR monetization event.